• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

涉及唐氏综合征患者和非唐氏综合征患者阿尔茨海默病神经退行性变的信号通路。

Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.

机构信息

Department of Physiology and Pharmacology, Faculty of Medicine, University of Cantabria, 39011 Santander, Spain.

出版信息

Int J Mol Sci. 2020 Sep 20;21(18):6906. doi: 10.3390/ijms21186906.

DOI:10.3390/ijms21186906
PMID:32962300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7555886/
Abstract

Down syndrome (DS), the most common cause of intellectual disability of genetic origin, is characterized by alterations in central nervous system morphology and function that appear from early prenatal stages. However, by the fourth decade of life, all individuals with DS develop neuropathology identical to that found in sporadic Alzheimer's disease (AD), including the development of amyloid plaques and neurofibrillary tangles due to hyperphosphorylation of tau protein, loss of neurons and synapses, reduced neurogenesis, enhanced oxidative stress, and mitochondrial dysfunction and neuroinflammation. It has been proposed that DS could be a useful model for studying the etiopathology of AD and to search for therapeutic targets. There is increasing evidence that the neuropathological events associated with AD are interrelated and that many of them not only are implicated in the onset of this pathology but are also a consequence of other alterations. Thus, a feedback mechanism exists between them. In this review, we summarize the signalling pathways implicated in each of the main neuropathological aspects of AD in individuals with and without DS as well as the interrelation of these pathways.

摘要

唐氏综合征(Down syndrome,DS)是最常见的遗传性智力障碍病因,其特征为中枢神经系统形态和功能发生改变,这些改变从早期产前阶段就开始出现。然而,到了人生的第四个十年,所有患有 DS 的人都会出现与散发性阿尔茨海默病(Alzheimer's disease,AD)相同的神经病理学表现,包括由于 tau 蛋白过度磷酸化而导致的淀粉样斑块和神经原纤维缠结的形成、神经元和突触的丧失、神经发生减少、氧化应激增强以及线粒体功能障碍和神经炎症。有人提出,DS 可能是研究 AD 病因病理学和寻找治疗靶点的有用模型。越来越多的证据表明,与 AD 相关的神经病理学事件是相互关联的,其中许多不仅与该病理学的发生有关,而且也是其他改变的后果。因此,它们之间存在反馈机制。在这篇综述中,我们总结了在患有和不患有 DS 的个体的 AD 的主要神经病理学方面涉及的信号通路,以及这些通路之间的相互关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ab/7555886/b474f2c490b6/ijms-21-06906-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ab/7555886/b474f2c490b6/ijms-21-06906-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ab/7555886/b474f2c490b6/ijms-21-06906-g001.jpg

相似文献

1
Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.涉及唐氏综合征患者和非唐氏综合征患者阿尔茨海默病神经退行性变的信号通路。
Int J Mol Sci. 2020 Sep 20;21(18):6906. doi: 10.3390/ijms21186906.
2
Brain insulin resistance in Down syndrome: Involvement of PI3K-Akt/mTOR axis in early-onset of Alzheimer's disease and its potential as a therapeutic target.唐氏综合征中的脑胰岛素抵抗:PI3K-Akt/mTOR 轴在阿尔茨海默病早期发病中的作用及其作为治疗靶点的潜力。
Biochem Biophys Res Commun. 2024 Nov 12;733:150713. doi: 10.1016/j.bbrc.2024.150713. Epub 2024 Sep 17.
3
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.唐氏综合征合并阿尔茨海默病患者淀粉样斑块中补体蛋白的时间累积。
Am J Pathol. 2000 Feb;156(2):489-99. doi: 10.1016/S0002-9440(10)64753-0.
4
Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice.抗白介素 17 治疗可改善唐氏综合征小鼠表型。
Brain Behav Immun. 2018 Oct;73:235-251. doi: 10.1016/j.bbi.2018.05.008. Epub 2018 May 31.
5
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.唐氏综合征小鼠模型中 Dyrk1A 基因剂量的正常化可挽救几种阿尔茨海默病表型。
Neurobiol Dis. 2017 Oct;106:76-88. doi: 10.1016/j.nbd.2017.06.010. Epub 2017 Jun 21.
6
Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome.脑胰岛素抵抗引发唐氏综合征的早发性阿尔茨海默病。
Neurobiol Dis. 2020 Apr;137:104772. doi: 10.1016/j.nbd.2020.104772. Epub 2020 Jan 24.
7
Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.唐氏综合征患者中与年龄相关的阿尔茨海默病神经退行性变和神经元丢失的发育缺陷和动态分期。
Acta Neuropathol Commun. 2022 Jan 4;10(1):2. doi: 10.1186/s40478-021-01300-9.
8
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.唐氏综合征尸检脑组织中 tau 和淀粉样蛋白 PET 示踪剂的区域结合。
Mol Neurodegener. 2020 Nov 23;15(1):68. doi: 10.1186/s13024-020-00414-3.
9
HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.唐氏综合征中HNE修饰的蛋白质:与阿尔茨海默病神经病理学发展的关联。
Free Radic Biol Med. 2017 Oct;111:262-269. doi: 10.1016/j.freeradbiomed.2016.10.508. Epub 2016 Nov 10.
10
Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.解析唐氏综合征患者大脑中神经退行性变的复杂性:蛋白质组学的见解。
Proteomics Clin Appl. 2014 Feb;8(1-2):73-85. doi: 10.1002/prca.201300066.

引用本文的文献

1
Alzheimer's Disease: Exploring the Landscape of Cognitive Decline.阿尔茨海默病:探索认知衰退的全貌。
ACS Chem Neurosci. 2024 Nov 6;15(21):3800-3827. doi: 10.1021/acschemneuro.4c00339. Epub 2024 Oct 11.
2
Maternal choline supplementation rescues early endosome pathology in basal forebrain cholinergic neurons in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.母体胆碱补充可挽救唐氏综合征和阿尔茨海默病 Ts65Dn 小鼠模型基底前脑胆碱能神经元中的早期内体病理学。
Neurobiol Aging. 2024 Dec;144:30-42. doi: 10.1016/j.neurobiolaging.2024.09.002. Epub 2024 Sep 6.
3
Drug Repurposing: A Leading Strategy for New Threats and Targets.

本文引用的文献

1
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials.唐氏综合征中的抗氧化剂:从临床前研究到临床试验
Antioxidants (Basel). 2020 Aug 3;9(8):692. doi: 10.3390/antiox9080692.
2
A multi-level developmental approach to exploring individual differences in Down syndrome: genes, brain, behaviour, and environment.一种探索唐氏综合征个体差异的多层次发展方法:基因、大脑、行为与环境。
Res Dev Disabil. 2020 Sep;104:103638. doi: 10.1016/j.ridd.2020.103638. Epub 2020 Jul 10.
3
The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease.
药物重新利用:应对新威胁和新靶点的首要策略。
ACS Pharmacol Transl Sci. 2024 Apr 1;7(4):915-932. doi: 10.1021/acsptsci.3c00361. eCollection 2024 Apr 12.
4
Overlap in synaptic neurological condition susceptibility pathways and the neural pannexin 1 interactome revealed by bioinformatics analyses.生物信息学分析揭示了突触神经疾病易感性途径和神经 Pannexin 1 相互作用组的重叠。
Channels (Austin). 2023 Dec;17(1):2253102. doi: 10.1080/19336950.2023.2253102. Epub 2023 Oct 8.
5
A Triterpenoid Lupeol as an Antioxidant and Anti-Neuroinflammatory Agent: Impacts on Oxidative Stress in Alzheimer's Disease.三萜卢佩醇作为一种抗氧化和抗神经炎症的药物:对阿尔茨海默病氧化应激的影响。
Nutrients. 2023 Jul 7;15(13):3059. doi: 10.3390/nu15133059.
6
The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer's Disease: Therapeutic Implications and Future Perspectives.阿尔茨海默病病理生理学中氧化应激、线粒体功能障碍与神经炎症之间的联系:治疗意义与未来展望
Antioxidants (Basel). 2022 Oct 31;11(11):2167. doi: 10.3390/antiox11112167.
7
Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome.儿茶素作为一种预防与唐氏综合征相关的合并症的潜在膳食补充剂。
Nutrients. 2022 May 12;14(10):2039. doi: 10.3390/nu14102039.
8
β-Arrestin2 Is Critically Involved in the Differential Regulation of Phosphosignaling Pathways by Thyrotropin-Releasing Hormone and Taltirelin.β- arrestin2 在促甲状腺素释放激素和塔尔替林对磷酸信号通路的差异调节中起关键作用。
Cells. 2022 Apr 27;11(9):1473. doi: 10.3390/cells11091473.
9
Network-based stage-specific drug repurposing for Alzheimer's disease.基于网络的阿尔茨海默病阶段特异性药物再利用
Comput Struct Biotechnol J. 2022 Mar 16;20:1427-1438. doi: 10.1016/j.csbj.2022.03.013. eCollection 2022.
10
[Differential expression profile of miRNAs in amniotic fluid exosomes from fetuses with Down syndrome].[唐氏综合征胎儿羊水外泌体中微小RNA的差异表达谱]
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Feb 20;42(2):293-299. doi: 10.12122/j.issn.1673-4254.2022.02.18.
CREB 和 BDNF 在神经生物学和阿尔茨海默病治疗中的作用。
Life Sci. 2020 Sep 15;257:118020. doi: 10.1016/j.lfs.2020.118020. Epub 2020 Jun 27.
4
Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer's Disease.小胶质细胞与Wnt信号通路:阿尔茨海默病炎症反应的研究前景
Front Aging Neurosci. 2020 May 14;12:110. doi: 10.3389/fnagi.2020.00110. eCollection 2020.
5
G-Protein Coupled Receptors and Tau-different Roles in Alzheimer's Disease.G蛋白偶联受体与Tau蛋白在阿尔茨海默病中的不同作用
Neuroscience. 2020 Jul 1;438:198-214. doi: 10.1016/j.neuroscience.2020.04.019. Epub 2020 Apr 23.
6
Glucose, glycolysis, and neurodegenerative diseases.葡萄糖、糖酵解与神经退行性疾病。
J Cell Physiol. 2020 Nov;235(11):7653-7662. doi: 10.1002/jcp.29682. Epub 2020 Apr 2.
7
Cellular Senescence in Neurodegenerative Diseases.神经退行性疾病中的细胞衰老
Front Cell Neurosci. 2020 Feb 11;14:16. doi: 10.3389/fncel.2020.00016. eCollection 2020.
8
Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.唐氏综合征临床前模型中药物治疗的转化有效性及意义。
Prog Brain Res. 2020;251:245-268. doi: 10.1016/bs.pbr.2019.10.001. Epub 2019 Nov 1.
9
Down syndrome.唐氏综合征。
Nat Rev Dis Primers. 2020 Feb 6;6(1):9. doi: 10.1038/s41572-019-0143-7.
10
Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome.脑胰岛素抵抗引发唐氏综合征的早发性阿尔茨海默病。
Neurobiol Dis. 2020 Apr;137:104772. doi: 10.1016/j.nbd.2020.104772. Epub 2020 Jan 24.